The clinical and basic pharmacology of mivacurium: a short-acting nondepolarizing benzylisoquinolinium diester neuromuscular blocking drug.
Mivacurium is a benzylisoquinolinium diester. The drug is a nondepolarizing relaxant which is hydrolysed by plasma cholinesterase at 70-88% of the rate of suxamethonium. Enzymatic hydrolysis gives the drug its short duration of action. The length of paralysis is about 2-2.5 times that of suxamethonium and one-half to one-third that of the intermediate-acting nondepolarizers. The development of mivacurium represents a collaboration between industrial pharmacologists and chemists at Burroughs Wellcome Co. (USA) and investigators at the Massachusetts General Hospital, Boston, MA, USA.
New York Hospital-Cornell University Medical Center, New York, USA.
J J
JJ
Savarese
C A
CA
Lien
M R
MR
Belmont
L
L
Rubin
D002802:Cholinesterases / Q000097:blood; D015195:Drug Design; D004345:Drug Industry; D006207:Half-Life; D006769:Hospitals, General; D006801:Humans; D006868:Hydrolysis; D007546:Isoquinolines / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D000077590:Mivacurium; D003473:Neuromuscular Nondepolarizing Agents / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D013390:Succinylcholine / Q000493:pharmacokinetics
D007546:Isoquinolines; D003473:Neuromuscular Nondepolarizing Agents; D000077590:Mivacurium; D002802:Cholinesterases; D013390:Succinylcholine